208 related articles for article (PubMed ID: 28616676)
1. [Liquid biopsy : A blood sample for early recognition and therapy control in lung cancer patients].
Hekmat K; Bruns C
Chirurg; 2017 Jul; 88(7):621. PubMed ID: 28616676
[No Abstract] [Full Text] [Related]
2. Biomarker studies abound for early detection of lung cancer.
Brower V
J Natl Cancer Inst; 2009 Jan; 101(1):11-3. PubMed ID: 19116384
[No Abstract] [Full Text] [Related]
3. Tumor-educated platelet as liquid biopsy in lung cancer patients.
Liu L; Lin F; Ma X; Chen Z; Yu J
Crit Rev Oncol Hematol; 2020 Feb; 146():102863. PubMed ID: 31935617
[TBL] [Abstract][Full Text] [Related]
4. [Finding mutations of interest in circulating tumor DNA helps predict immunotherapy response in lung cancer].
Guibert N; Pradines A; Favre G; Mazières J
Med Sci (Paris); 2020 May; 36(5):437-439. PubMed ID: 32452359
[No Abstract] [Full Text] [Related]
5. MIRA analysis of RARβ2 gene methylation in DNA circulating in the blood in lung cancer.
Kapitskaya KY; Azhikina TL; Ponomaryova AA; Cherdyntseva NV; Vlasov VV; Laktionov PP; Rykova EY
Bull Exp Biol Med; 2014 Aug; 157(4):516-9. PubMed ID: 25110096
[TBL] [Abstract][Full Text] [Related]
6. Reproducibility of a semiquantitative measurement of circulating DNA in plasma from neoplastic patients.
Frattini M; Balestra D; Verderio P; Gallino G; Leo E; Sozzi G; Pierotti MA; Daidone MG
J Clin Oncol; 2005 May; 23(13):3163-4; author reply 3164-5. PubMed ID: 15860889
[No Abstract] [Full Text] [Related]
7. Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples.
Ishii H; Azuma K; Sakai K; Kawahara A; Yamada K; Tokito T; Okamoto I; Nishio K; Hoshino T
Oncotarget; 2015 Oct; 6(31):30850-8. PubMed ID: 26334838
[TBL] [Abstract][Full Text] [Related]
8. Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients.
Malapelle U; Mayo de-Las-Casas C; Rocco D; Garzon M; Pisapia P; Jordana-Ariza N; Russo M; Sgariglia R; De Luca C; Pepe F; Martinez-Bueno A; Morales-Espinosa D; González-Cao M; Karachaliou N; Viteri Ramirez S; Bellevicine C; Molina-Vila MA; Rosell R; Troncone G
Br J Cancer; 2017 Mar; 116(6):802-810. PubMed ID: 28170370
[TBL] [Abstract][Full Text] [Related]
9. Role of circulating-tumor DNA analysis in non-small cell lung cancer.
Jiang T; Ren S; Zhou C
Lung Cancer; 2015 Nov; 90(2):128-34. PubMed ID: 26415994
[TBL] [Abstract][Full Text] [Related]
10. Prognostic role of K-Ras mutations in non-small cell lung cancer: still an issue for open debate.
Neri M; Cesario A; Granone P; Dominioni L; Puntoni R; D'Angelillo RM; Russo P
Lung Cancer; 2006 Sep; 53(3):393-5; author reply 397-8. PubMed ID: 16887233
[TBL] [Abstract][Full Text] [Related]
11. EGFR array: uses in the detection of plasma EGFR mutations in non-small cell lung cancer patients.
Yam I; Lam DC; Chan K; Chung-Man Ho J; Ip M; Lam WK; Chan TK; Chan V
J Thorac Oncol; 2012 Jul; 7(7):1131-40. PubMed ID: 22610259
[TBL] [Abstract][Full Text] [Related]
12. Serum sMICA as biomarker in detection of non-small-cell lung carcinoma.
Xing S; Zhu Y; Sun Y
Br J Biomed Sci; 2018 Jan; 75(1):50-52. PubMed ID: 29182468
[No Abstract] [Full Text] [Related]
13. Circulating DNA is a useful prognostic factor in patients with advanced non-small cell lung cancer.
Sirera R; Bremnes RM; Cabrera A; Jantus-Lewintre E; Sanmartín E; Blasco A; Del Pozo N; Rosell R; Guijarro R; Galbis J; Sánchez JJ; Camps C
J Thorac Oncol; 2011 Feb; 6(2):286-90. PubMed ID: 21252717
[TBL] [Abstract][Full Text] [Related]
14. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.
Villaflor V; Won B; Nagy R; Banks K; Lanman RB; Talasaz A; Salgia R
Oncotarget; 2016 Oct; 7(41):66880-66891. PubMed ID: 27602770
[TBL] [Abstract][Full Text] [Related]
15. Role of quantitative and qualitative characteristics of free circulating DNA in the management of patients with non-small cell lung cancer.
Ulivi P; Silvestrini R
Cell Oncol (Dordr); 2013 Dec; 36(6):439-48. PubMed ID: 24177991
[TBL] [Abstract][Full Text] [Related]
16. Rapid clearance of circulating tumor DNA during treatment with AZD9291 of a lung cancer patient presenting the resistance EGFR T790M mutation.
Vallée A; Audigier-Valette C; Herbreteau G; Merrien J; Tessonnier L; Théoleyre S; Denis MG
Lung Cancer; 2016 Jan; 91():73-4. PubMed ID: 26612314
[No Abstract] [Full Text] [Related]
17. Tumour marker evaluation in patients with lung cancer.
Seregni E; Botti C; Bogni A; Bombardieri E
Scand J Clin Lab Invest Suppl; 1995; 221():67-71. PubMed ID: 7652492
[No Abstract] [Full Text] [Related]
18. Significance of Serum MicroRNAs in the Auxiliary Diagnosis of Non-Small Cell Lung Cancer.
Shi GL; Chen Y; Sun Y; Yin YJ; Song CX
Clin Lab; 2017 Jan; 63(1):133-140. PubMed ID: 28164492
[TBL] [Abstract][Full Text] [Related]
19. Circulating free DNA concentration is an independent prognostic biomarker in lung cancer.
Tissot C; Toffart AC; Villar S; Souquet PJ; Merle P; Moro-Sibilot D; Pérol M; Zavadil J; Brambilla C; Olivier M; Couraud S
Eur Respir J; 2015 Dec; 46(6):1773-80. PubMed ID: 26493785
[TBL] [Abstract][Full Text] [Related]
20. A blood-based test for epidermal growth factor receptor mutations in lung cancer.
Bell DW; Haber DA
Clin Cancer Res; 2006 Jul; 12(13):3875-7. PubMed ID: 16818680
[No Abstract] [Full Text] [Related]
[Next] [New Search]
